Business Context and Reporting Period
Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended March 31, 1998
Business Overview: BD operates in two primary segments: Medical Supplies and Devices ("Medical") and Diagnostic Systems ("Diagnostic"). The company reported strong operational performance driven by product mix improvements and productivity gains, though results were impacted by foreign currency translation.
Key Financial Metrics
| Metric | Q2 1998 | Q2 1997 | 6 Months 1998 | 6 Months 1997 |
|---|---|---|---|---|
| Revenues | $738.4 million | $699.2 million | $1,440.1 million | $1,355.0 million |
| Net Income | $92.3 million | $82.7 million | $156.7 million | $140.8 million |
| Diluted EPS | $0.71 | $0.63 | $1.21 | $1.08 |
| Operating Income | $144.5 million | $121.7 million | $247.6 million | $208.1 million |
| Gross Margin | 50.7% | 49.6% | 50.1% | 48.6% |
| Operating Margin | 19.6% | 17.4% | 17.2% | 15.4% |
| Cash from Operations (6mo) | $241.7 million (vs. $209.3 million prior year) | |||
| Total Debt | $798.0 million (Short-term: $233.8M; Long-term: $564.2M) | |||
| Cash & Equivalents | $113.1 million (as of March 31, 1998) |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 6% year-over-year for both the quarter and the six-month period. Excluding the unfavorable impact of a stronger U.S. dollar (estimated at $26 million for the quarter), organic revenue growth was approximately 9-10%.
- Segment Performance:
- Medical Segment: Revenues grew 2% (quarter) and 5% (six months). Growth was driven by infusion therapy and injection systems.
- Diagnostic Segment: Revenues grew 10% (quarter) and 8% (six months), aided by prior-year acquisitions. Domestic Diagnostic revenues surged 21%.
- Profitability: Gross profit margins improved by over 1 percentage point in both periods due to a more profitable product mix and productivity improvements. Selling and administrative expenses decreased as a percentage of revenue.
- Acquisitions: The company completed the acquisition of IntelliCode and Tru-Fit in the second quarter for approximately $25 million. A subsequent event noted the completion of the Ohmeda Medical Devices Division acquisition on April 3, 1998, for approximately $452 million.
- Capital Allocation: Capital expenditures increased to $90 million for the six months ended March 31, 1998, compared to $63 million in the prior year. The company repurchased $44 million of common stock during the period.
Guidance, Outlook, and Risks
- Capital Expenditures: Full-year capital expenditures are expected to be slightly higher than the prior year's $170 million.
- Share Repurchases: The company expects to limit share repurchases for the remainder of the year, with authorization remaining for an additional 10.6 million shares.
- Year 2000 Compliance: BD expects to spend $6 million to $10 million to modify and replace computer software for Year 2000 compliance. Costs are not expected to materially affect results of operations. Remediation is targeted for completion by mid-1999.
- Enterprise Systems Initiative: A new seven-year, $160 million initiative was approved to implement a global software system and common business practices.
- Risks: Management highlighted risks including competitive factors, economic conditions, interest rate fluctuations, foreign currency exchange rates, product introduction delays, and changes in healthcare regulations. There is also a risk regarding the Year 2000 readiness of third-party entities with which BD interfaces.
Investor Verification Checklist
- Verify the impact of the $452 million Ohmeda acquisition (completed April 3, 1998) on future revenue and integration costs.
- Monitor the execution of the $160 million enterprise-wide systems initiative and its impact on operating expenses over the next seven years.
- Assess the sustainability of the improved gross margins (50.7% in Q2) given the mix of products sold.
- Review the status of Year 2000 remediation efforts, particularly regarding external supplier and customer interfaces.
- Track the company's leverage ratio (currently 34.6% of total capital) in light of recent acquisition financing and future capital expenditure plans.